Final Marketing Authorization Decision by the European Medicines Agency

The European Medicines Agency (EMA) has granted final marketing authorization for Izamby, a denosumab biosimilar developed by Spanish biopharma company mAbxience. Izamby targets RANKL (receptor activator of nuclear factor-kappa B ligand), a protein that promotes the formation and activation of osteoclasts—cells that break down bone—thereby increasing bone density and significantly reducing the risk of fractures. It demonstrated high similarity to the originator drug, Amgen's Prolia, and met the rigorous efficacy and safety standards of European regulatory authorities. This approval is clinically significant as it allows the entry of a cost-effective biosimilar into the large osteoporosis market, which is approaching patent expiry, thereby reducing patients' medication costs and enhancing treatment accessibility.

Fresenius Kabi's Strategy in the Biosimilar Market

mAbxience, the developer of Izamby, is a company in which Fresenius Kabi, a subsidiary of the German global healthcare group Fresenius SE & Co. KGaA (ticker FRE), holds a 55% stake. Fresenius Kabi has been actively shifting its portfolio from traditional intravenous solutions and generic injectables to high-value biosimilars as a next-generation growth driver. This approval marks a significant milestone for Fresenius Kabi, and when combined with its strong hospital distribution network and marketing capabilities in Europe, is expected to lead to rapid market penetration. Successful establishment in the European market will increase the biosimilar segment's contribution to Fresenius Kabi's revenue, thereby driving long-term profitability improvements across the Fresenius Group.

Changing Global Market Dynamics and Amgen's Defensive Strategy

Prolia, the originator drug containing denosumab, is a blockbuster medication with global sales of $4.41 billion in 2025 and holds a significant market share in Europe. However, the launch of biosimilars like Izamby has placed Amgen (ticker AMGN), the originator developer, under dual pressure to defend its market share and manage pricing. Amgen is actively implementing defensive strategies, including patient switching marketing to its pipeline products, to minimize revenue erosion. Investors should closely monitor how quickly Izamby can erode the originator market and the intensity of price competition during the market share acquisition process.

Intensifying Denosumab Biosimilar Market Competition

Currently, in global markets such as Europe and the U.S., Sandoz's Wyost and Jubbonti have already secured early approvals and are aiming to capture market share. mAbxience's Izamby, as a late entrant, will need to engage in fierce competition with these early players. Celltrion in South Korea is also accelerating its market entry with its own biosimilar. In this multi-player competitive landscape, Izamby must strategically pursue insurance reimbursement and pricing negotiations with health authorities in European countries such as Spain and Germany to drive early prescriptions. Given that governments are actively promoting biosimilar prescriptions to reduce healthcare spending, Izamby's initial distribution strategy, including price competitiveness and a stable supply chain, will be a key determinant of its success.